Payment overview · 2025
General Payments
$535.25
25 reported records · 12 companies
Healthcare provider profile · identity verified
Juanito E Savaille, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · CHILLICOTHE, OH · NPI 1467885061
Verified facts
What the public records show
CMS Open Payments records show Juanito E Savaille, D.O. received $535.25 in general payments during 2025 across 25 reported records.
Lilly USA, LLC accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.41 | 18.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.34 | 15.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.88 | 11.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.54 | 11.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $55.62 | 10.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$44.70 | 8.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.41 | 7.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.00 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.30 | 3.4% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $16.13 | 3.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.64 | 2.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.28 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $490.25 | 24 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $55.62 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $44.70 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $42.77 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $29.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 129 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
129 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
109 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
172 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 549 | 160 |
| Gabapentin | Gabapentin | 453 | 88 |
| Omeprazole | Omeprazole | 423 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 99 |
| Losartan Potassium | Losartan Potassium | 333 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 82 |
| Lisinopril | Lisinopril | 269 | 81 |
| Furosemide | Furosemide | 257 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 240 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 57 |
| Simvastatin | Simvastatin | 189 | 49 |
| Eliquis | Apixaban | 172 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 169 | 22 |
| Metformin Hcl | Metformin Hcl | 168 | 52 |
| Jardiance | Empagliflozin | 159 | 33 |
| Spironolactone | Spironolactone | 158 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 135 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 34 |
| Mounjaro | Tirzepatide | 129 | 23 |
| Metformin Hcl Er | Metformin Hcl | 128 | 39 |
| Potassium Chloride | Potassium Chloride | 128 | 36 |
| Allopurinol | Allopurinol | 114 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 32 |
| Trulicity | Dulaglutide | 109 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 106 | 27 |
| Alprazolam | Alprazolam | 104 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 104 | 32 |
| Carvedilol | Carvedilol | 100 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 32 |
| Trazodone Hcl | Trazodone Hcl | 98 | 32 |
| Sertraline Hcl | Sertraline Hcl | 96 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 31 |
| Glimepiride | Glimepiride | 93 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | 25 |
| Xarelto | Rivaroxaban | 90 | 18 |
| Tramadol Hcl | Tramadol Hcl | 88 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 83 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 22 |
| Famotidine | Famotidine | 75 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 23 |
| Pregabalin | Pregabalin | 72 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 20 |
| Ozempic | Semaglutide | 67 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 66 | 14 |
| Lorazepam | Lorazepam | 64 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 61 | 17 |
| Clonazepam | Clonazepam | 58 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 48 |
| Montelukast Sodium | Montelukast Sodium | 52 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 51 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 16 |
| Finasteride | Finasteride | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 49 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 49 | suppressed |
| Atenolol | Atenolol | 48 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Glipizide Er | Glipizide | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Methylprednisolone | Methylprednisolone | 45 | 41 |
| Valsartan | Valsartan | 45 | 13 |
| Meclizine Hcl | Meclizine Hcl | 44 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | 11 |
| Bupropion Xl | Bupropion Hcl | 43 | 14 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 31 |
| Azithromycin | Azithromycin | 33 | 31 |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Prednisone | Prednisone | 32 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | 11 |
| Glipizide | Glipizide | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Diazepam | Diazepam | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Nystatin | Nystatin | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Single Use Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | 11 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 13 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $535.25 · 25 records | Lilly USA, LLC | AIRSUPRA, AREXVY, CeQur Simplicity, Cologuard Collection Kit, FARXIGA, JARDIANCE, Kerendia, MAVYRET, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error